An effectiveness of erdosteine for management of cough in patients with community acquired pneumonia: the results of MUCASTAT trial
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: to investigate an effectiveness and tolerability of mucoactive drugs’ adding for management of cough in hospitalized patients with community acquired pneumonia on the background of standard antibacterial treatment.
Patients and methods. 103 patients (36 men and 67 women) aged 27–82 years were included in open comparative study. All the patients received standard antibacterial treatment for 7–10 days and were randomized in groups for additional taking of erdosteine (Mucitus) or ambroxol in standard dosages for 5–10 days. CAP-Sym-12 questionnaire was used to estimate pneumonia related symptoms.
Results. In 2–3 days from the beginning of therapy the patients from erdosteine group began to estimate their well being (condition) and cough intensity (according to CAP-Sym-12 questionnaire) better, than patients from ambroxol group. In subsequent observation periods (in 7±1 and 12±2 days from the beginning of treatment) superiority of erdosteine was documented by objective (lesser quantity of patients suffering from cough sputum expectoration) and subjective methods (CAP-Sym-12 questionnaire).
Conclusion. Erdosteine is effective, better then ambroxol and well tolerated medicine for management of cough in hospitalized patients with community acquired pneumonia on the background of standard antibacterial treatment.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Наказ No 128 від 19.03.2007 р. Про затвердження клінічних протоколів надання медичної допомоги за спеціальністю «Пульмонологія» / Міністерство охорони здоров’я (МОЗ) України. – Офіц. вид. – К., 2007. – 146 с. – (Нормативний документ МОЗ України. Протокол).
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community acquired pneumonia in adults / L.A. Mandell, R.G. Wunderink, A. Anzueto [et al.] // Clin. Infect. Dis. – 2007. – Vol. 44. – P. S2–S27.
Guidelines for the management of adult lower respiratory tract infections / M. Woodhead, F. Blasi, S. Ewig [et al.] // Clin. Microbiol. Infect. – 2011. – Vol. 17, Suppl. 6. – P. E1–E59.
Over the counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults / C.C. Chang, A.C. Cheng, A.B. Chang // Cochrane Database Syst Rev. – 2012. – Issue 2. – Art. No.: CD006088.
Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease // Expert. Rev. Resp. Med. – 2007. – Vol. 1, No. 3. – P. 307–316.
Smith J. Cough and its importance in COPD / J. Smith, A. Woodcock // Int. J. COPD. – 2006. – Vol. 1, No. 3. – P. 305–314.
Березняков И.Г. Кашель: от диагноза к лечению. – К.: ООО Вистка, 2017. – 204 с.
The community acquired pneumonia symptom questionnaire: a new, patient-based outcome measure to evaluate symptoms in patients with community acquired pneumonia / D.L. Lamping, S. Schroter, P. Marquis [et al.] // Chest. – 2002. – Vol. 122, No. 3 – Р. 920–929.
Лебединська М.М. Особливості якості життя пацієнтів із негоспітальною пневмонією та супутньою хронічною серцевою недостатністю / М.М. Лебединська, Н.В. Кумпан // Медицина транспорту України. – 2013. – No 2. – C. 64–66.
Duration of antibiotic treatment in community acquired pneumonia: a multicenter randomized clinical trial / A. Uranga, P.P. Espaсa, A. Bilbao et al. // JAMA Intern. Med. – 2016. – Vol. 176. – P. 1257–65.
Березняков І.Г. Особливості перебігу нетяжкої негоспітальної пневмонії в осіб із супутньою хронічною серцевою недостатністю / І.Г. Березняков, М.М. Лебединська // Болезни и антибиотики. – 2013. – No 1. – С. 36–48.
Корж А.Н. Эффективность ступенчатой терапии у больных с внебольничными пневмониями с сопутствующей хронической сердечной недостаточностью / А.Н. Корж, В.И. Березняков // Болезни и антибиотики. – 2013. – No 1. – С. 13–22.
National Institute for Health and Care Excellence. Pneumonia (including community acquired pneumonia). 2014. Доступно по адресу: www.nice.org.uk/guidance/cg191
Malerba M. Ambroxol in the 21st century: pharmacological and clinical update / M. Malerba, B. Ragnoli // Expert. Opin. Drug Metab. Toxicol. – 2008. – V. 4. – P. 1119–1129.
Cazzola M. The therapeutic efficacy of erdosteine in the treatment of chronic obstructive bronchitis: a meta analysis of individual patient data / M. Cazzola, I. Floriani, C.P. Page // Pulmon. Pharmacol. Ther. – 2010. – V. 23, No. 2. – P. 135–144.
Dal Negro R.W.Efficacy and safety of erdosteine in COPD: Results of a 12 month prospective, multinational study / R.W. Dal Negro, M. Iversen, P.M.A. Calverly // Eur. Resp. J. – 2015. – DOI: 10.1183/13993003.congress-2015.PA1495
Moretti M. Erdosteine reduces inflammation and time to first exacerbation postdischarge in hospitalized patients with AECOPD / M. Moretti, S. Fagnani // Int. J. COPD. – 2015. – Vol. 10. – P. 2319–2325.
